Bifogade filer
Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, Sweden – November 3, 2025— Modus Therapeutics Holding AB (publ) (“Modus” or the “Company”) announces that the competent authorities in Italy have approved the Company’s dose selection for its ongoing Phase IIa study evaluating sevuparin in patients with anemia associated with chronic kidney disease (CKD). This approval enables initiation of Part 2 (repeat-dose; proof-of-concept) in Q4 2025, in line with previously communicated plans.
What the approved amendment covers
Final dose selection: Three sevuparin doses are specified for Part 2, based on single-dose data from Part 1. The Part 2 dose levels pertain to patients with CKD stages 3–5. Data from Part 1 also indicate that no sevuparin dose adjustment is required for patients with CKD stages 1–2 (mild CKD).
Safety data: In Part 1, sevuparin was well tolerated regardless of kidney function, with no treatment discontinuations or clinically meaningful safety signals.
Timeline: With this approval, Part 2 remains on track to start in Q4 2025 as planned.
CEO comment
“The protocol approval is an important milestone for our CKD program. We can now proceed to repeat dosing in patients and evaluate sevuparin’s clinical potential in CKD with anemia. This keeps us on our planned timeline to start Part 2 in Q4 2025.”
— John Öhd, CEO
About the study
The ongoing Phase IIa study is conducted at two leading nephrology centers in Italy (Verona and Pavia) together with the CRO partner Latis S.r.l. Part 1 (single dose) provided the basis for dose selection and design ahead of Part 2.
Medical need and rationale
Preclinical and translational findings show that sevuparin can lower hepcidin, improve hematologic parameters, and modulate markers of kidney injury/fibrosis—supporting development in CKD with anemia, where novel hepcidin-targeted therapies are needed.
Next steps
Site activation and patient screening for Part 2 (repeat dosing, PoC) are intended to start in Q4 2025. Business development activities continue in parallel with study execution.